Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Cisplatin + Durvalumab + Etoposide + Tremelimumab & Small-Cell-Lung-Cancer (SCLC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

The combination of durvalumab, with or without tremelimumab, plus platinum-etoposide has been studied in the treatment of extensive-stage small-cell lung cancer (ES-SCLC).

References (Sources)

Durvalumab plus platinum–etoposide versus platinum–etoposide in ﬁrst-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase III trial
Paz-Ares et al. 2019a Lancet 394: 1929-1939
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Goldman et al. 2021 The Lancet Oncology 22: 51-65
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer
Mathieu et al. 2021

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Cisplatin + Durvalumab + Etoposide + Tremelimumab & Small-Cell-Lung-Cancer (SCLC)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat